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Treatment and Prevention of Common Complications of
Chronic Kidney Disease obstruction, tubulo-interstitial nephropathy and infiltrative diseases. Studies in South Asian countries including Bangladesh have shown glomerulonephritis to be the most common cause of end stage renal disease (ESRD) followed by DM. [3] [4] [5] The most frequent cause of CKD in North America and Europe is DM followed by hypertension. 6 Diabetes mellitus is now becoming increasingly prevalent in developing countries, perhaps due to change in dietary habits, diminished physical activity and weight gain. 6 Therefore, DM is now the leading cause of ESRD requiring renal replacement therapy (RRT) in many parts of the world, and its prevalence is increasing disproportionately in the developing world. 6 Patients with newly diagnosed CKD often also present with hypertension. When no overt evidence for a primary glomerular or tubulointerstitial kidney disease process is present, CKD is often attributed to hypertension. 6 The incidence of ESRD in our country is not known, but would be much higher than that in developed countries because of high incidence of infection and environmental pollution as well as increasing prevalence of DM.
This article critically reviews the current recommendations and therapeutic strategies published in recent journals and various clinical guidelines for treatment and preventing or delaying the progression of CKD and it's common complications.
Definition of chronic kidney disease
The National Kidney Foundation (NKF), an organization in United States defines CKD as either kidney damage or decreased kidney function for 3 months or more. 7 The definition of CKD is the same regardless of age, sex and race. This definition is widely accepted and has been adopted in various clinical guidelines. 2, [8] [9] [10] [11] [12] [13] Decreased kidney function means a glomerular filtration rate (GFR) of less than 60 mL p e r minute per 1.73 m 2 body surface area. 7 A GFR rate of more than 60 mL/min/1.73 m 2 i s considered abnormal if it is accompanied by documented evidence of kidney damage. The principal marker of kidney damage is the presence of persistent protein in urine. Other evidence of kidney damage includes abnormalities in urine sediment, blood and urine biochemistry, or abnormal findings in imaging studies. 7 CKD can also be defined by the presence of urinary albumin in an excretion rate higher than 300 mg per 24 hours (macroalbuminuria) or urinary protein excretion 0.5 g/24 hours or more (significant proteinuria). [7] [8] [9] 14 H o wever, microalbuminuria or 24-hour urinary albumin excretion in the range of 30 to 300 mg indicates the early stage of kidney disease in DM. 15 
Glomerular filtration rate (GFR)
The GFR is the best measure of overall kidney function. 7 The normal level of GFR varies according to age, sex, and body size. In healthy young adult of 30 years or younger, the normal GFR is approximately 125 mL/min per 1.73 m 2 and declines by approximately 1 mL/min per 1.73 m 2 per year thereafter. 7 Estimation of the GFR no longer requires a 24-hour urine collection for creatinine clearance; it can be accomplished with similar accuracy using mathematic formulas. Most commonly used formulas are the Modification of Diet in Renal Disease (MDRD) equation and the CockcroftGault equation (Table I ). Many laboratories now report an estimated GFR (eGFR), using one of these equations. The MDRD has the advantage of being more accurate than the Cockcroft-Gault in persons with a GFR less than 90 mL/min per 1.73 m 2 and takes race into consideration. 7, 16, 17 At GFR below 60 mL/min, the prevalence of complications of CKD increases. [18] [19] [20] However, in people aged over 70 years, an eGFR in the range 45-59 mL/min/1.73 m 2 , if stable over time and without any other evidence of kidney damage, is unlikely to be associated with CKD related complications. 2 
Stages of CKD
The NKF classifies CKD into five stages (Table II) based on the GFR and/or presence of kidney damage. 7 This staging system is widely accepted by various clinical guidelines on the management of chronic kidney disease. 2, [8] [9] [10] [11] [12] [13] 
Complications
The complications of CKD tend to occur at relatively predictable stages of disease as noted in Table III 
Management
Maintenance of euvolemia (fluid balance) It has been suggested to limit sodium intake for its effects on both fluid balance and blood pressure. 24, 25 In advanced CKD, the kidney is unable to adapt to large changes in sodium intake. Intake >3-4 g/day can lead to hypertension and volume overload, whereas intake of <1 g/day can lead to volume depletion and hypotension. A goal of 2 g/day of sodium is reasonable for most patients. A daily intake of 2 L of fluid maintains water balance. 25 But overzealous salt restriction or diuretic use can lead to extracellular fluid volume depletion and precipitate a further decline in GFR. Patients with salt-losing nephropathy may require a sodium-rich diet or salt supplementation. 6, 24 Hyperkalemia Hyperkalemia often responds to dietary restriction of potassium, avoidance of potassium supplements as well as potassium-retaining medications [especially spironolactone, angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor blockers (ARBs)], or the use of kaliuretic diuretics such as metolazone. Metolazone promotes urinary potassium excretion, while a potassium-binding resin, such as calcium resonium or sodium polystyrene, promotes potassium loss through the gastro-intestinal tract and may reduce the incidence of hyperkalemia in CKD patients. 25 a) Acute hyperkalemia: calcium chloride or gluconate intravenously, insulin administration with glucose intravenously, bicarbonate intravenously, and potassium-binding resin orally or per rectum, cardiac monitoring. 25 Intractable hyperkalemia is an indication (although uncommon) to consider institution of dialysis in a CKD patient. 25 b) Chronic hyperkalemia: dietary potassium restriction and sodium polystyrene, 15-30 g once daily orally in juice or sorbitol. 25 
Acidemia
It has been suggested that in presence of acidemia oral alkali therapy can slow CKD progression. 25 The plasma bicarbonate should be maintained >22 mmol/L by giving sodium bicarbonate supplements (starting dose of 1 g 8-hourly, increasing as required). 6,24 I t m u st be remembered that the increased sodium intake may induce hypertension or edema. 24 
Hypertension
Hypertension is commonly associated with CKD in more than 75% of patients. 26 Various target blood pressures have been suggested, for example, 130/80 mm Hg or less for CKD alone, and lowered to 125/75 mm Hg for those with proteinuria >1 g/day. 6, 7, 24, 27, 28 In CKD if hypertension is associated with significant proteinuria (0.5 g/24 h or more), ACE inhibitors/ ARBs should be offered because of their unique ability to decrease proteinuria preferentially by lowering intra-glomerular pressure. 2, 27 In hypertension with urinary protein excretion <0.5 g/24 h, ACE inhibitors, ARBs, long-acting calcium channel blockers, thiazide diuretics or beta-blockers can be used. 2 When ACE inhibitor/ARB therapy is started, some patients with CKD may have an initial decrease in GFR, a mild increase in the serum creatinine concentration, and a mild increase in the potassium level. 29 Therefore, in people with CKD, serum creatinine and potassium levels should be measured and the GFR should be estimated before starting ACE inhibitor/ARB therapy. These measurements should be repeated between 7 th and 14 th day after starting ACE inhibitor/ARB therapy and after each dose increase. 2 ACE inhibitor/ARB therapy should not normally be started if the pretreatment serum potassium concentration is significantly above the normal reference range. Often the concomitant use of a kaliuretic diuretic can improve potassium excretion in addition to improving blood pressure control. 2 25 ESAs are less effective in the presence of iron deficiency, active inflammation, malignancy, intercurrent illness, or in patients with aluminium overload, which may occur in dialysis. 24 The use of ESAs for the treatment of anemia in patients with CKD is associated with potential adverse outcomes, including increased blood pressure, thrombotic complications (like stroke) and possibly other CVD events. 25, 27 b) Iron therapy is an important component of anemia management. Iron supplementation is usually essential to ensure an optimal response to ESAs in patients with CKD because the demand for iron by the marrow frequently exceeds the amount of iron that is immediately available for erythropoiesis (measured by percent transferrin saturation), as well as the amount in iron stores (measured by serum ferritin). In CKD, a serum ferritin <100 ng/mL or iron saturation <20% is suggestive of iron deficiency. 25 Iron stores should be repleted prior to the initiation of ESAs. For the CKD patient not yet on dialysis, oral iron supplementation should be attempted. If there is GI intolerance, the patient may have to undergo intravenous (IV) iron infusion. 6 People receiving ESA maintenance therapy should be given iron supplements to keep their serum ferritin levels between 200 and 500 ng/mL. 2 Iron therapy should probably be withheld if the serum ferritin is >500 ng/mL, even if the iron saturation is <20%. 25 Oral therapy with ferrous sulfate, gluconate, or fumarate, 325 mg once to three times daily, is the initial therapy in CKD. 25 
Antiplatelet drugs
Antiplatelet drugs should be offered to people with CKD for the secondary prevention of CVD. 2
Hyperuricemia
There is also theoretic value in lowering uric acid levels in CKD patients with concomitant hyperuricemia, but clinical data regarding benefit are still lacking. 25 
Nutrition
Counseling on adequate and appropriate nutrition should be provided at each office visit. Dietary advice should be offered to people with progressive CKD concerning protein, calorie, salt, potassium and phosphate intake, when indicated. 2 a) Protein intake: The effect of dietary protein restriction on kidney disease is the subject of debate.
There is a lack of convincing evidence that the longterm restriction of protein intake (<0.70 g/kg/day) delays the progression of CKD. 6, 27 Nonetheless, restriction of dietary protein intake has been recommended for CKD patients. For non-diabetic and diabetic patients with CKD stage 4, two systematic reviews and one meta-analysis suggested that, in comparison to other treatments, there was, at most, a modest benefit associated with restricting protein leading to a delay in CKD progression. 37, 38 High protein intakes are associated with high phosphate intakes as foods that contain protein also tend to contain phosphate. It would appear prudent to avoid high protein intakes in stage 4 CKD patients when hyperphosphatemia is prevalent. The ADA recommends reduction of protein intake to 0.8-1.0 g/kg body wt/day in individuals with diabetes and the earlier stages of CKD and to 0.8 g/kg body wt/day in the later stages of CKD that may improve renal function. 39 Current recommendations from the NKF K/DOQI and other studies suggest a protein intake of 0.8 to 1.0 g/kg/day in patients with CKD. 7, [40] [41] [42] It is further advised that at least 50% of the protein intake be of high biologic value. 6 Benefits of protein restriction in slowing decline of GFR must be weighed against the risk of malnutrition and cachexia upon the initiation of dialysis. 25 b) Energy intake: An adequate nutrition with daily caloric intake of 30 to 35 kcal per kg/day in patients with CKD has been recommended. 6, 7 c) Salt and water restriction: A goal of 2 g/day of sodium intake is reasonable for nondialysis patient approaching ESRD; a daily intake of 2 L of fluid maintains water balance. 25 Patients with salt-losing nephropathy may require a sodium-rich diet or salt supplementation. 6 d) Potassium restriction: A goal of <50-60 mEq/day intake of potassium is adequate. Restriction is needed once the GFR has fallen below 10-20 mL/min/1.73 m 2 , or earlier if the patient is hyperkalemic. 25 e) Phosphorus restriction: Phosphorus needs to be restricted to 800-1000 mg/day. Foods rich in phosphorus such as cola beverages, eggs, dairy products, nuts, beans, and meat should be limited, although care must be taken to avoid protein malnutrition. 25 P h osphorus-containing medicines, particularly cathartics should be avoided. 25 f) Magnesium-containing medications, such as laxatives and antacids are contraindicated. Many drugs are excreted by the kidney; dosages should be adjusted for GFR. 25 Lifestyle advice Most patients with CKD will die of events related to CVD before ESRD develops. 43 Therefore, an important focus of care for patients with CKD includes management of cardiovascular risk factors. People with CKD should be encouraged at each office visit to take regular exercise, achieve a healthy weight and stop smoking completely. Smoking is a strong risk factor for cardiovascular mortality in patients with CKD. 44 It is also strongly associated with the progression of nephropathy. 44 A t a rget weight of BMI <23 should be ideal. 2
Treatment of underlying cause for preventing progression of CKD Treatment of the underlying cause of CKD is vital. These include optimized glucose control in diabetes mellitus, immunomodulatory agents for glomerulonephritis, and emerging specific therapies to retard cytogenesis in polycystic kidney disease. 6, 25 Diabetes Control of diabetes should be aggressive in early CKD; excellent glycemic control reduces the risk of kidney disease and its progression. 25 The American Diabetes Association (ADA) and Canadian guidelines recommend that plasma values for preprandial glucose be kept in the 5.0-7.2 mmol/L (90-130 mg/dL) range and hemoglobin A 1C should be <7% to prevent progression of CKD in patients with DM. 27, 45 The half-life of insulin is prolonged in CKD due to reduced tubular metabolism of insulin; patients on insulin therapy may need progressive reduction in dose as their renal function worsens. Risk of hypoglycemia increases in advanced CKD, and glycemic targets may need to be relaxed to avoid this dangerous complication. 24 M a ny hypoglycemic agents such as metformin require dose reduction in renal failure, and some are contraindicated when the GFR is <50 mL/min/1.73 m 2 . 25 Metformin can cause lactic acidosis; and the thiazolidinediones (e.g., pioglitazone) may increase renal salt and water absorption and aggravate volume-overload states, and contribute to adverse cardiovascular events. 6 ACE inhibitors or ARBs should be used in individuals with microalbuminuria as well as with macroalbuminuria irrespective of presence of hypertension in diabetes. 9 ACE inhibitors and ARBs are effective at reducing proteinuria, slowing the decline in GFR and retarding the progression of diabetic kidney disease. 2 The definition of hypertension in DM or diabetic kidney disease (DKD) is blood pressure of 130/80 mm Hg or greater. 46 
Key clinical recommendations
Early detection and management of CKD can prevent kidney disease progression and decrease its complications. All patients should be assessed to determine their susceptibility to or development of CKD. The clinical evaluation should include analysis for risk factors, markers of CKD (e.g. assessment for persistent a l buminuria), GFR estimation, and a treatment plan to slow the progression. Key clinical recommendations for treatment, prevention and delaying the progression of CKD and its complications are: a) According to the evidence, ACE inhibitors/ARBs have been shown to reduce proteinuria a n d the occurrence of kidney failure. 2, 29, [47] [48] [49] [50] b) Evidence suggests that ACE inhibitors are more effective than other antihypertensive drugs in preventing the progression of kidney disease in diabetic and nondiabetic patients. [51] [52] [53] [54] c) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommends a target blood pressure of less than 130/80 mm Hg in patients with chronic kidney disease. 28 d) To prevent progression of nephropathy in patients with DM, the ADA recommends glycemic control, with the goal being a HbA1C <7 percent. 45 e) The most recent guidelines from the NKF recommend treating dyslipidemia aggressively in patients with CKD. The goals are a LDL cholesterol level below 100 mg per dL (2.60 mmol/L) and a triglyceride level below 200 mg per dL ( 2 .26 mmol/L). 36 f) Anemia in CKD responds to ESAs. Iron therapy is an important component of anemia management in CKD. The target goal of Hb is 10-11 g/dL. 25 In CKD patients, where kidney transplant is a treatment option, red cell transfusions should be avoided if possible. 2 g) Epidemiologic studies in humans show an association between elevated phosphorus levels and increased risk of cardiovascular mortality in early CKD through ESRD. 25 C o ntrol of hyperphosphatemia is the first step in the treatment of CKD-MBD. 25 While using calcium-based phosphorus binders, hypercalcemia must be avoided to prevent aggravation of soft tissue and vascular calcification leading to increased cardiovascular morbidity and mortality.
h) Protein restriction may be effective in slowing the progression of CKD, especially proteinuric and diabetic renal diseases. Benefits of protein restriction in slowing decline of GFR must be weighed against the risk of malnutrition and cachexia upon the initiation of dialysis. 25 
Conclusion
The incidence of CKD is increasing worldwide and unfortunately, CKD is often undetected and undertreated because of its insidious onset, variable progression, and length of time to overt kidney failure. Its natural course is an eventual decline in the GFR, leading to kidney failure and the need for RRT. The goal of therapy is to detect CKD early to delay its progression, thereby reducing associated complications and adverse outcomes of kidney disease. Patients with one or more risk factors should have their GFR estimated and be assessed for persistent albuminuria. Evidence supports that achieving optimal glucose control, blood pressure, and reduction in albuminuria slows the progression of CKD. 7, 10, 28, [55] [56] [57] [58] [59] ACE inhibitors are more effective than other antihypertensive drugs i n preventing the progression of kidney disease in diabetic and nondiabetic patients. Other interventions studied to reduce progression include correction of anemia, treatment of CKD-MBD, dietary protein restriction, and lipid-lowering therapy.
